A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801

Patrick J. Morris a,*, Richard D. Burke b, Alok K. Sharma b, Daniel C. Lynch b, Leslie E. Lemke-Boutcher c, Shiny Mathew d, Ikram Elayan d, Deepa B. Rao d, i, Todd D. Gould a, i, Carlos A. Zarate Jr. 1, Panos Zanos g, Ruin Moaddel h, Craig J. Thomas a

a Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA
b Covance Laboratories, Inc., Madison, WI 53704, USA
c Division of Pharmacology/Toxicology Neuroscience, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
d Departments of Psychiatry, Pharmacology, and Anatomy & Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
e Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
f Department of Psychiatry, Pharmacology, and Physiology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA
g Biomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
h Veterans Affairs Maryland Health Care System, Baltimore, MD, USA

ARTICLE INFO

Keywords:
Neurotoxicology
NMDAR antagonists
Olney lesions
Ketamine
Pharmacokinetics
MK-801
Neuropathology

ABSTRACT

With the increasing use of ketamine as an off-label treatment for depression and the recent FDA approval of (S)-ketamine for treatment-resistant depression, there is an increased need to understand the long-term safety profile of chronic ketamine administration. Of particular concern is the neurotoxicity previously observed in rat models following acute exposure to high doses of ketamine, broadly referred to as ‘Olney’s lesions’. This type of toxicity presents as abnormal neuronal cellular vacuolization, followed by neuronal death and has been associated with ketamine’s inhibition of the N-methyl-D-aspartate receptor (NMDAR). In this study, a pharmacological and neuropathological analysis of ketamine, the potent NMDAR antagonist MK-801, and the ketamine metabolite (2R,6R)-hydroxynorketamine [(2R,6R-HNK)] in rats is described following both single dose and repeat dose drug exposures. Ketamine dosing was studied up to 20 mg/kg intravenously for the single-dose neuropathology study and up to 60 mg/kg intraperitoneally for the multiple-dose neuropathology study. MK-801 dosing was studied up to 0.8 mg/kg subcutaneously for both the single and multiple-dose neuropathology studies, while (2R,6R-HNK) dosing was studied up to 160 mg/kg intravenously in both studies. These studies confirm dose-dependent induction of ‘Olney’s lesions’ following both single dose and repeat dosing of MK-801. Ketamine exposure, while showing common behavioral effects, did not induce wide-spread Olney’s lesions. Treatment with (2R,6R-HNK) did not produce behavioral effects, toxicity or any evidence of Olney’s lesion formation. Based on these results, future NMDAR-antagonist neurotoxicity studies should strongly consider taking pharmacokinetics more thoroughly into account.

1. Introduction

Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, has emerged as an effective therapy for treatment-resistant depression (Zarate Jr et al., 2006; Newport et al., 2015; Wilkinson et al., 2017). Its use as an acute and maintenance treatment is rapidly increasing for both depression and other indications such as bipolar disorder and post-traumatic stress disorder (Wilkinson et al., 2017). The increasing use of ketamine (i.e. racemic ketamine: a mixture of (R)-ketamine and (S)-ketamine) and the recent FDA approval of intranasal (S)-ketamine to treat major depressive disorder (MDD) has fueled concerns around these drugs’ acute and long-term toxicities (Strong and Kabbaj, 2018). In
addition, the use ketamine for depression has been administered through a variety of routes, including intravenous, intranasal, intramuscular, and subcutaneous, with different outcomes from each route of administration (Loo et al., 2016). Despite its value in treating depression, ketamine has several detrimental side effects, including its abuse liability, dissociation properties, and potential to induce cognitive deficits (Strong and Kabbaj, 2018). One potential neurological risk derived from the use of NMDAR antagonists is the development of a specific type of NMDAR antagonist neurotoxicity, also known as ‘Olney’s lesions’ (Olney et al., 1989). Originally identified by Olney and coworkers, this toxicity results from the administration of moderate to high doses of NMDAR antagonists, including PCP, MK-801, ketamine, and tiletamine and is described as vacuolization in the neurons of the retrolspinal cortex and posterior cingulate gyrus in rats (Olney et al., 1989; Olney et al., 1991). Vacuoles are heterogeneous in size (3–15 μm in diameter) and located within the cytoplasmic compartment of the neurons, which appear to originate from the saccules of the endoplasmic reticulum (Olney et al., 1989). Following short-term administration, lesion formation is reversible, however long-term treatment with NMDAR antagonists can induce irreversible neuronal necrosis of affected brain regions (Olney et al., 1989, Olney et al., 1991). Such damage is revealed through hematoxylin and eosin staining which exposes necrotic neurons with brightly eosinophilic, severely shrunken cytoplasm and pyknotic or karyorrhectic nuclei (Fix et al., 1993). By 4 days after dosing with MK-801 the necrotic neurons are often surrounded by reactive microglial cells (Fix et al., 1993). Later experiments identified increased HSP70 and HSP72 levels as biomarkers that correlate with NMDAR antagonism (Fix et al., 1993; Sharp et al., 1991; Sharp et al., 1992; Tian et al., 2018).

Pronounced strain (Fix et al., 1995), age and sex (Auer, 1996) differences have been identified in the development of this neurotoxicity, with older rats and female rats being more susceptible (Auer, 1996). A human study on subjects with a history of ketamine abuse also showed neural degeneration (Wang et al., 2013), reinforcing the potential for neurotoxicity in individuals who repeatedly use NMDAR antagonists. Vacuole formation is difficult to confirm in humans as neuronal vacuolization is transient and likely difficult to observe in post-mortem human brains. Given the difficulty in confirming the presence of Olney’s lesions in human subjects, it’s imperative that we expand upon preclinical models in hopes of better assessing the neuronal toxicity of this highly useful class of drugs (Green and Cote, 2009). The shift from short duration, single-use ketamine administration for anesthesia to repeated, subanesthetic use of ketamine to treat depression, pain, and other indications intensifies this need.

For this study, we focused on the pharmacology, behavioral effects, and neurotoxicity of ketamine in rats. We employed a multiple dosing paradigm to better mimic the human antidepressant administration regime and assessed the effects on neurotoxicity. We included MK-801, a potent NMDAR antagonist which has been associated with neurotoxicity, as a positive control. For MK-801, the (+)-MK 801 enantiomer was utilized as it yields the lesions more readily than its enantiomer. We also included the ketamine metabolite [(2R,6R)-hydroxynorketamine ([2R,6R]-HNK) in this study. Substantial preclinical evidence shows that [(2R,6R)-HNK possesses antidepressant-like activity in mouse models without appreciable activity as an NMDAR antagonist at pharmacologically-relevant concentrations (Zanos et al., 2016; Zanos et al., 2018; Fukumoto et al., 2019; Lumsden et al., 2019; Riggs et al., 2020). However, there are some inconsistencies in the reported effects of [(2R,6R)-HNK in tests predictive of antidepressant effectiveness (Highland et al., 2021). Each agent used in this study was subjected to extensive pharmacokinetic analysis in hopes of better understanding how drug exposure relates to Olney’s lesion formation.

2. Materials and methods

2.1. Study design

The experiments were designed as three separate studies: a single-dose, pharmacokinetic study; a single-dose neuropathology study; and a multiple-dose neuropathology study. The pharmacokinetic study was designed to understand the differences in compound exposure levels for each agent with special consideration given to the differences in route of administration and established differences based on animal sex. It was performed in Sprague-Dawley rats in order to better correspond to the strain most often used in the literature (Olney et al., 1989; Olney et al., 1991; Jevtovic-Todorovic et al., 2000; Jevtovic-Todorovic et al., 2001). The single-dose neuropathology study was designed to examine the formation of Olney’s lesions or necrotic neurons via neuropathology at rapid and delayed time points (nominally referred to as 3 or 72 h postdose; actual necropsy/perfusion ranged from 3 to 3.33 or 72 ± 1 h postdose, respectively). The multiple-dose neuropathology study was designed to dose the animals twice a week for 2 weeks, and examine the animals for the formation of Olney’s lesions of necrotic neurons via neuropathology at three time points: 3 h after the first dose; 3 h after the last dose; and 72 h after the last dose. Time points were selected on the basis of the current literature, which suggests that the reversible neuronal vacuolization is most robust at 3–4 h after dose administration, while the neuronal necrosis is most evident at 3–4 days post dosing (Olney et al., 1989; Olney et al., 1991; Fix et al., 1993). The neuropathology studies were performed in Han Wistar rats in order to align with a concurrent toxicology program (data not included). All experimental treatments were administered unblinded. Animals were assigned to the treatment groups randomly.

2.2. Animals

Food and water were available ad libitum. For the neuropathology studies, Han Wistar rats (12–14 weeks of age at time of dosing, Envigo, RMS, Inc) were acclimated to the test facility for 7–18 days. Pharmacokinetic studies used 36 Sprague Dawley rats (11–15 weeks of age, 18 male, 18 female, Envigo RMS Inc.), with 3 male and 3 female animals per group which were acclimated to the test facility for 2–5 days. Neuropathology studies used 858 total animals (286 Male, 572 female, 12–14 weeks old at initial of dosing, including replacement animals) with 20 female animals per group for the single dose study and 40 female animals (30 neuropathology and 10 satellite) per group in the multiple dose study. Additionally, for the negative control group and [(2R,6R)-HNK dosing cohorts 20 male animals per group were used for the single dose study and 40 male animals (30 neuropathology and 10 satellite) per group for the multiple dose study. Animals were group-housed (up to three animals/sex/cage) in polycarbonate cages. Animals were monitored for abnormal clinical observations, including changes in behavior, at least three times daily during infil. In addition, on days of dose administration, animals were monitored at least 10, 30, and 60 min post dose. Animals administered MK-801 were continuously monitored for at least 2 h following dose administration. Body weights were recorded and monitored. All procedures were performed in facilities fully accredited by the AAALAC, were in compliance with applicable animal welfare acts and were approved by the appropriate Institutional Animal Care and Use Committee (IACUC).

2.3. Compounds, formulation, and dosing

[(2R,6R)-HNK was utilized as [(2R,6R)-hydroxynorketamine hydrochloride (National Center for Advancing Translational Sciences). Ketamine was utilized as ketamine hydrochloride (Tocris Biosciences or Sigma Aldrich). MK-801 was utilized as (+)-MK 801 maleate (Tocris Biosciences). For pharmacologic studies, compounds and controls were dissolved in normal saline (0.9% w/v) until they formed a clear or
colorless solution. \( (2R,6R)\)-HNK and ketamine were formulated at 2 mg/ml final concentration. MK-801 was formulated at 0.1 mg/ml final concentration. The purpose of MK-801 was to serve as a positive control for histological staining (rather than for the test articles) to ensure that lesions, when present, could be detected. Compounds were dosed using intravenous (IV), intraperitoneal (IP) or subcutaneous (SC) routes of administration as described, with SC injection in the scapular region and with ketamine IV injection via the tail vein as a slow bolus over 60 s.

For the neuropathology studies, \( (2R,6R)\)-HNK was formulated in a 75 mM sodium phosphate buffer, pH 7 to avoid injection of a drug substance outside of safe pH ranges. \( (2R,6R)\)-HNK was administered as an IV infusion via tail vein over 20 min on days 1, 4, 11, and 15. Ketamine was formulated in 75 mM sodium phosphate buffer, pH 7 and was administered as an IV slow bolus (approximately 60–90 s) via the tail vein in the single-dose study. In the multiple dose study, ketamine was administered as an IV injection on days 1, 4, 11, and 15. MK-801 was formulated in sterile water for injection, and was administered as a SC injection near the scapular region, with injections on days 1, 4, 7, and 15 for the multiple dose study. The negative control was a 75 mM sodium phosphate buffer, pH 7, prepared in sterile 0.45% (w/v) saline. This negative control was administered as an IV infusion via the tail vein over 20 min, with injections on day 1, 4, 7, and 15 for the multiple dose study.

2.4. Sample collection and analysis

Pharmacokinetic analyses were performed from blood collected via jugular vein-cannula by syringe and transferred into tubes containing K2ETDA. Samples were collected prior to dosing, and at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 h after dosing. Blood was centrifuged within 1 h of collection, and the resulting plasma was placed in 96 well tubes, and stored at –70 °C to –80 °C. Plasma samples were analyzed by liquid chromatography-mass spectrometry (LC-MS/MS) for \( (2R,6R)\)-HNK, ketamine, or MK-801 concentrations as appropriate.

2.5. Neuropathology

For single dose studies, animals were euthanized either 3 h after dosing or 72 h after dosing. For multiple dose studies, animals were euthanized at 3 h after dosing on day 1, 3 h after dosing on day 15, or 72 h after dosing on day 15. For the multiple dose studies, animals were fasted overnight prior to euthanasia. Animals were anesthetized with sodium pentobarbital, exsanguinated via upper body perfusion with heparinized sodium nitrate saline, followed by 4% paraformaldehyde fixative. The brain was removed, divided into 7 sections as previously described as the recommended practices for sampling and processing the nervous system (Rao et al., 2011; Bolon et al., 2013), and paraffin embedded within 72 h after fixation. Slides were made of the brain at a thickness of 5 μM. Slides were stained using hematoxylin and eosin, fluorojade-B, or immunostained using Iba-1 (Abcam cat # Ab5076) and GFAP (Life technologies cat # 003218). Histopathological examination included a qualitative evaluation for vacuolation (H&E) and necrosis (H&E and Fluoro Jade B). Relative changes in immunolabeling for Iba-1 (ionized Ca-binding protein) and GFAP (glial fibrillary acidic protein) were also based on subjective (increase or decrease) comparisons to the control group.

2.6. Data and statistical analysis

Pharmacokinetic calculations were performed using Microsoft Excel (Microsoft, Redmond, WA) and PKSolver (Zhang et al., 2013). Non-compartmental analysis was applied to determine the following parameters: \( C_{0} \) (Back-extrapolated concentration at time 0); \( C_{max} \) (Maximum observed concentration); \( T_{max} \) (time of maximum observed concentration); \( AUC_{0-t} \) (Area under the concentration-time curve from hour 0 to the last measurable concentration, estimated by the linear trapezoidal rule); \( AUC_{0-inf} \) (Area under the concentration time curve from hour 0 to infinity, calculated as \( AUC_{0-t} + C_{0}/\lambda_{2} \) where \( C_{0} \) is the last measurable concentration and \( \lambda_{2} \) is the elimination rate constant estimated using log-linear regression during the terminal elimination phase); \( t_{1/2} \) (Elimination half-life determined by \( ln(2)/\lambda_{2} \)); \( CL \) (Clearance, calculated as Dose/\( AUC_{0-inf} \)). \( V_a \) (Volume of distribution at steady-state, calculated as CL \* \( MRT_{0-inf} \) \( MRT_{0-inf} \) is defined as the mean residence time for the drug.) CL/F (apparent total clearance after non-intravenous administration); and \( V_s/F \) (Apparent volume of distribution during the terminal phase after non-intravenous administration).

Table 1 reports selected parameters, as mean values (\( N = 3 \) unless otherwise noted). Other abbreviations as follows: M (males); F (females); IV (intravenous); IP (intraperitoneal); SC (subcutaneous).

Pharmacokinetic data was used to generate pharmacokinetic charts (Fig. 1) utilizing GraphPad Prism 8 to show the 0–4 or 0–24 h time window as appropriate, with mean values and standard deviations displayed. Statistical significance was calculated using the unpaired t-test (GraphPad Prism 8) for comparing \( AUC \) values for male and female groups (Table S1). One * indicates \( p < 0.05 \), ** indicates \( p < 0.01 \), *** indicates \( p < 0.001 \). For statistical significance in the neuropathological evaluation, the Fisher’s exact test was utilized.

3. Results

3.1. Behavioral effects of \( (2R,6R)\)-HNK, ketamine, and MK-801 in pharmacokinetic studies

\( (2R,6R)\)-HNK, ketamine, and MK-801 were administered to different groups of animals, with each group comprised of 3 female and 3 male animals (Table 1). \( (2R,6R)\)-HNK and ketamine were administered at a dose of 10 mg/kg, while MK-801 was administered at a dose of 0.5 mg/kg. Administration of \( (2R,6R)\)-HNK was not associated with hyperactivity or ataxia in either male or female animals. IV administration of ketamine generated hyperactivity in both male and female animals, which resolved within 1 h. SC administration of ketamine at the same dose had no behavioral effects. IV and IP MK-801 administration led to ataxia in male animals which resolved by 6–7 h after administration. Female animals given the same MK-801 dose became severely ataxic shortly after administration and became non-responsive by 4–6 h. According to IACUC guidelines, all female animals were euthanized at 5.5–6 h due to lack of improvement. SC dosing of MK-801 also caused ataxia in both male and female animals. In the male animals, the ataxia began to resolve by 4 h after administration. Ataxia persisted in the female groups past 8 h but resolved by 24 h after administration.

3.2. Pharmacokinetic analysis of \( (2R,6R)\)-HNK, ketamine, and MK-801

In both male and female groups, plasma levels of \( (2R,6R)\)-HNK (10 mg/kg) showed rapid drug elimination, with concentrations dropping from over 5000 ng/ml to under 500 ng/ml in less than an hour (Fig. 1, Table 1). No significant differences in drug exposure were found in male versus female animals (Fig. S1).

The pharmacokinetic parameters of ketamine (10 mg/kg) were assessed using both IV and SC administration. IV administration resulted in a higher \( C_{max} \) in both sexes compared to SC administration (Table 1, Fig. 1). However, there was no significant difference in the \( AUC \) values between the SC and IV ketamine administration (\( p = 0.19 \)). Female animals demonstrated significantly higher levels of ketamine compared to male animals following both SC and IV administration (Table 1, Fig. S1).

The pharmacokinetic parameters of MK-801 (0.5 mg/kg) were assessed using three different routes of administration (IV, IP, and SC). With all three routes of administration, levels of MK-801 were significantly higher in female animals compared to male animals (Table 1, Fig. S1). This difference was most pronounced in the SC dosing, where
female animals demonstrated an AUC level almost 5-fold above those found in male animals.

3.3. Single dose neuropathology study of (2R,6R)-HNK, ketamine, and MK-801

The posterior cingulate and retrosplenial cortices, regions both known to be affected by NMDAR antagonist neurotoxicity (Olney et al., 1989; Horvath et al., 1997), were assessed 3 h and 72 h after a single dose of ketamine, (2R,6R)-HNK, or MK-801. IV injection of ketamine at doses higher than 20 mg/kg led to a high rate of mortality in female animals. Thus, the maximum dose used to assess acute neurotoxicity was 20 mg/kg of ketamine given by IV administration. At this dose, acute ketamine showed no neuronal vacuolization or necrosis, and Iba-1 immunostaining showed no evidence of microglial activation in female or male animals.

SC administration of MK-801 (0.5 mg/kg) resulted in neuronal vacuolization in the retrosplenial cortex of all rats by 3 h after dosing, (Fig. 2A-C, Fig. S2, Table 2). Vacuolization was observed in the posterior cingulate gyrus in 50% of the animals at the higher MK-801 dose. By 72 h after dosing, neuronal necrosis was present in 8 of the 9 animals within the retrosplenial cortex as resolved by hematoxylin and eosin staining (H&E) and by fluorojade-B staining (Fig. 2D-I, Table 2, see Fig. S3 for an example of the necrosis). Iba-1 labelling revealed microglial activation in 8 of the 9 rats at the higher MK-801 dosing (Fig. 2J-L, Table 2).

No neuropathological changes were observed in any animals after IV injection of (2R,6R)-HNK, even at doses up to 160 mg/kg (Table 2).

3.4. Multiple dose neuropathology study of (2R,6R)-HNK, ketamine, and MK-801

We next performed multiple dose neuropathology studies in rats as a
**Fig. 2.** Representative neuropathology images after single dosing of saline or MK-801 in the retrosplenial cortex A) H&E staining, saline dose, 3 h time point. B) H&E staining, 0.5 mg/kg MK-801, 3 h time point. The small arrow designates vacuolization in the cells. C) H&E staining, 0.8 mg/kg MK-801, 3 h time point. Note the more pronounced vacuolization. D) H&E staining, saline dose, terminal euthanization. E) H&E staining, 0.5 mg/kg MK-801, terminal euthanization. F) H&E staining, 0.8 mg/kg MK-801, terminal euthanization. Note the necrosis pointed by the arrows. G) Fluorojade staining, saline dose, terminal euthanization. H) Fluorojade staining, 0.5 mg/kg MK-801, terminal euthanization. I) Fluorojade staining, 0.8 mg/kg MK-801, terminal euthanization. Note the necrotic neurons observed by fluorojade staining. J) Iba-1 staining, saline dose, terminal euthanization. K) IBA1 staining, 0.5 mg/kg MK-801, terminal euthanization. L) Iba-1 staining, 0.8 mg/kg MK-801, terminal euthanization. Note the increase in Iba-1 staining. Bar length is 0.06 mm.

**Table 2**

Single dose neuropathology results.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Dose (mg/kg)</th>
<th>Route of administration</th>
<th>% animals with vacuolization</th>
<th>% animals with necrosis</th>
<th>% animals with increased Iba-1 labelling</th>
<th>% animals with increased GFAP labelling</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>3 h</td>
<td>72 h</td>
<td>3 h</td>
<td>72 h</td>
</tr>
<tr>
<td>Negative control</td>
<td>0</td>
<td>IV</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>(2R,6R)-HNK</td>
<td>12</td>
<td>IV</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>(2R,6R)-HNK</td>
<td>80</td>
<td>IV</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>(2R,6R)-HNK</td>
<td>120</td>
<td>IV</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Ketamine</td>
<td>3</td>
<td>IV</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Ketamine</td>
<td>10</td>
<td>IV</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Ketamine</td>
<td>20</td>
<td>IV</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>MK-801</td>
<td>0.5</td>
<td>SC</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>MK-801</td>
<td>0.8</td>
<td>SC</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
<td>88%</td>
</tr>
</tbody>
</table>

Ten animals/sex/group per timepoint per sex were utilized. The negative control and (2R,6R)-HNK groups utilized both male and female animals. The ketamine and MK-801 groups utilized only female animals.

* Administered as an intravenous infusion over 20 min.
* Administered as a slow intravenous injection over 60 s.
* Subcutaneous dosing.
* One of the 10 animals in the 72 h cohort died before the end of the study and was excluded.
model of repeat-dose ketamine administration in humans. For this study, animals were dosed twice a week for 2 weeks. Neuropathological changes were examined in the posterior cingulate and retrosplenial cortices at 3 h after the first dose, 3 h after the last dose (15 days; 363 h), and 72 h after the last dose (432 h). For this study, the ketamine route of administration was changed to IP dosing, which allowed for higher dosing levels without increasing acute lethality.

No neurotoxicity was observed at any dose or time point after (2R,6R)-HNK dosing, up to 160 mg/kg IV, or after ketamine dosing, up to 60 mg/kg IP (Table 3). The level of neuronal vacuolization at the 3-h time point following MK-801 administration was less pronounced relative to the single dose study. However, after multiple doses, the neuronal necrosis observed with MK-801 was more pronounced in both the number of animals affected at the 0.5 mg/kg dose (0% of animals with necrosis up to 60% of animals with necrosis, $p = 0.01$, Tables 2 and 3) and the relative severity of neuronal necrosis.

Analysis of Iba-1 immunostaining showed activation of microglia in animals in both MK-801 groups following repeat-dose administration. GFAP immunostaining showed astrogliosis in both MK-801 dosing groups, which was not observed in the single dose study (Figs. S4 and S5, Table 3). In addition, necrotic neurons were identified in the dentate gyrus of the hippocampus in one animal in the MK-801 0.8 mg/kg dosing group. Thus, multiple doses of MK-801 had greater neurotoxicity compared to single dose administration.

4. Discussion

This study provided an analysis of the neurotoxicity associated with both acute and multiple dose administration of (2R,6R)-HNK, ketamine, and MK-801 in rats, alongside detailed pharmacokinetic analysis, in order to more thoroughly understand the exact doses and exposure required for NMDAR antagonist-induced neurotoxicity. Dose ranges and different routes of administration were explored in order to elevate dosing to a highest achievable exposure of each drug as a means to demonstrate potential neurotoxicity outcomes and reflect clinical routes of administration (Loo et al., 2016). In this study, only MK-801 treatment induced the formation of Olney’s lesions and neurotoxicity. Notably, and consistent with published literature (Fix et al., 1995) a stark difference in the MK-801 pharmacokinetics was observed between male and female animals, with females having dramatically increased exposures (Fig. S1) and correspondingly more severe behavioral effects.

MK-801 administration resulted in dose-dependent Olney’s lesion formation and neuronal necrosis. In the initial pharmacokinetic experiments, MK-801 treated animals had an extended period of ataxia following IV, IP, or SC administration. These behavioral changes were so severe in female animals that animal welfare protocols required that the experiments be terminated after 6 h in the IV and IP administrations in females. It has been previously reported that female rats are far more sensitive to MK-801 than male rats, with higher rates of Olney’s lesion formation and neurotoxicity given the same dosing level of MK-801 (Auer, 1996). Our pharmacokinetics experiments demonstrate a profound sex difference in MK-801 exposure, especially with SC administration where the AUC in female animals was nearly five times that of the male animals, providing an explanation for the differential behavioral effects.

In contrast to MK-801, in the present study ketamine did not induce any detectable neurotoxicity at any of the doses or and routes of administration examined. The observation that ketamine does not induce Olney’s lesions is a divergence from previous studies including the original observations reported by Olney and coworkers (Olney et al., 1989; Olney et al., 1991). The incongruity between our results and other published studies may be related to differences in route of administration, dose and strain. Olney’s original reports primarily utilized a subcutaneous injection of ketamine in female Sprague-Dawley rats (Olney et al., 1989, Olney et al., 1991). By contrast, our neuropathology study utilized female Han Wistar rats, with either intraperitoneal or intraventricular routes of administration. Another comparative study, which did find lesion formation, used doses in excess of 40 mg/kg and intraperitoneal drug injection with rats (Jevtovic-Todorovic et al., 2001). Another study reported that intraperitoneal doses of 100 mg/kg in female rats were necessary to induce HSP-70 formation, a biomarker for NMDAR antagonist neurotoxicity (Tian et al., 2018). In contrast, in male rats an intraperitoneal dose of 50 mg/kg was necessary to induce HSP-70 formation (Tomitaka et al., 1996). Given the observation by Olney that female rats were more susceptible to Olney lesion induction, the exact correlation between HSP-70 induction and Olney lesion formation remains of interest (Olney et al., 1989; Jevtovic-Todorovic et al., 2000). Intrathecal injections of (S)-ketamine (0.7 mg/kg, once a day for 7 days) resulted in significant neurotoxicity in rabbits (Vranken et al., 2006). In a human case report, after repeated intrathecal injection of (S)-ketamine (20–50 mg), neurological damage to the spine was observed postmortem in an adult patient (Vranken et al., 2005). While the observed subarachnoid hemorrhage was attributed to the trauma of the catheter insertion, the authors found it unlikely that the observed spinal cord lesions were due to injection trauma (Vranken et al., 2005). To the best of our knowledge, there are no reports of neurotoxicity associated with IV ketamine administration in rodent models. As IV administration is the most common route of administration in humans, we endeavored to use this route of administration in this study. However, our studies were limited by unacceptable toxicity in female animals when using IV dosing of ketamine at/above 20 mg/kg. Using the IP route in the repeated dose study allowed ketamine dose levels to be increased to 60 mg/kg. However, within both the acute and chronic setting, the high-dose ketamine administrations (20 mg/kg IV and 60 mg/kg IP, respectively) did not

### Table 3

<table>
<thead>
<tr>
<th>Compound</th>
<th>Dose mg/kg</th>
<th>Route of administration</th>
<th>% animals with vacuolization</th>
<th>% animals with necrosis</th>
<th>% animals with increased Iba-1 labelling</th>
<th>% animals with increased GFAP staining</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>3 h 363 h 432 h</td>
<td>3 h 363 h 432 h</td>
<td>3 h 363 h 432 h</td>
<td>3 h 363 h 432 h</td>
<td>3 h 363 h 432 h</td>
</tr>
<tr>
<td>Negative control</td>
<td>NA</td>
<td>IV$^+$</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
</tr>
<tr>
<td>(2R,6R)-HNK</td>
<td>12</td>
<td>IV$^+$</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
</tr>
<tr>
<td>(2R,6R)-HNK</td>
<td>80</td>
<td>IV$^+$</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
</tr>
<tr>
<td>(2R,6R)-HNK</td>
<td>160</td>
<td>IV$^+$</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
</tr>
<tr>
<td>Ketamine</td>
<td>50</td>
<td>IP$^+$</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
</tr>
<tr>
<td>Ketamine</td>
<td>60</td>
<td>IP$^+$</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
<td>0% 0% 0%</td>
</tr>
<tr>
<td>MK-801</td>
<td>0.5</td>
<td>SC$^+$</td>
<td>0% 0% 0%</td>
<td>0% 100% 90%</td>
<td>0% 90% 40%</td>
<td>0% 100% 100%</td>
</tr>
<tr>
<td>MK-801</td>
<td>0.8</td>
<td>SC$^+$</td>
<td>0% 0% 0%</td>
<td>0% 100% 90%</td>
<td>0% 90% 40%</td>
<td>0% 100% 100%</td>
</tr>
</tbody>
</table>

Ten animals/sex/group per timepoint per sex were utilized. The negative control and (2R,6R)-HNK groups utilized both male and female animals. The ketamine and MK-801 groups utilized only female animals. 363 h represents Day 15, + 3 h. 432 h represents Day 15 + 72 h.

$^a$ Administered as an intravenous infusion over 20 min.

$^b$ Intraperitoneal injection.

$^c$ Subcutaneous dosing.
generate Olney’s lesion or neuronal necrosis. This suggests that IV or IP-administered ketamine does not achieve the necessary and/or sustained concentration needed to induce Olney’s lesions without also causing experiment-ending adverse events in Han Wistar rats.

Similarly, the ketamine metabolite (2R,6R)-HNK showed no neurotoxicity at any dose, even with repeat, high dose administration (160 mg/kg, IV). Some studies have demonstrated (2R,6R)-HNK can act as a partial NMDAR antagonist at high concentrations (50 μM) (Suzuki et al., 2017). However, our results are consistent with prior studies that show no effects of (2R,6R)-HNK on NMDAR activity at pharmacologically-relevant concentrations (Zanos et al., 2016; Lumsden et al., 2019) and minimal to no adverse side effects at much higher concentrations (Highland et al., 2021).

From a pharmacological perspective, the mechanism of NMDAR antagonist-induced neurotoxicity is not completely understood. There is evidence that high doses of NMDAR antagonists result in disinhibition of excitatory inputs to certain cholinergic neurons (Low and Roland, 2004). This loss of inhibitory control leads to excess cholinergic inputs to cortical glutamatergic neurons in the posterior cingulate (PC) and retrosplenial cortex (RC) in rats, leading to vacuolization and ultimately cell death within these cortical neurons (Low and Roland, 2004). Notably, while rats and mice demonstrate the most severe neurotoxicity in the PC and RC, other species demonstrate more severe NMDAR antagonist-induced neurotoxicity in alternate locations: guinea pigs within the frontoparietal neocortex (Raboisson et al., 1998b); mice (Bender et al., 2010a, 2010b; Wozniak et al., 1996); and canines within the piriform cortex (Low and Roland, 2004).

There is evidence that NMDAR antagonist-induced neurotoxicity is driven by the length of time the NMDAR is inhibited rather than the maximal concentration of the NMDAR antagonist (Bender et al., 2010b). Ketamine is rapidly eliminated in rats when dosed IV (Fig. 1, Table 1), and to a lesser extent IP, with levels dropping near to the lower limit of quantification within 2 h after IV administration and 3 h for IP administration (Saland and Kabbaj, 2018). However, when dosed subcutaneously, that length of time is extended to 4 h (Table 1, Fig. 1). Interestingly Olney observed that female rats were more susceptible to ketamine-induced Olney’s lesion formation when compared to male rats (Jevtovic-Todorovic et al., 2001). Both our data (Fig. S1) and Saland’s data (Saland and Kabbaj, 2018) demonstrate that ketamine has a significantly higher AUC in female rats compared to male rats. This is suggestive that the increased susceptibility for Olney lesion induction in female rats is due to ketamine’s pharmacokinetic differences between the sexes.

Simultaneous and delayed (up to 10 h) exposure to DNQX, a competitive antagonist at AMPA and kainate receptors, protected neurons from MK-801-induced neuronal necrosis (Bender et al., 2010b). However, a 24-h window between MK-801 and DNQX injections had no protective effects. When the neurotoxicity of the NMDAR antagonist nitrous oxide was tested, its administration over 12 h was required to induce neuronal necrosis (Jevtovic-Todorovic et al., 2001). Treatment with nitrous oxide for 8 h or less resulted in reversible vacuole formation, but minimal to no neuronal necrosis. Further experiments coupling pharmacokinetics with clinically utilized NMDAR antagonists are needed to better understand this enigmatic form of neurotoxicity.

5. Conclusions

Here we present an in-depth pharmacokinetic analysis of ketamine, (2R,6R)-HNK, and MK-801 as a means to better understand the NMDAR-antagonist-related neurotoxicity of each agent using different routes of administration and schedules. (2R,6R)-HNK demonstrated no adverse behavioral effects at the highest doses and no observed neurotoxicity. Ketamine administration reproduced well-established behavioral effects and high-dose lethality, however, previously reported NMDAR-antagonist neurotoxicity was not confirmed. MK-801 administration produced significant behavioral effects and dose-dependent neurotoxicity. Unlike ketamine and (2R,6R)-HNK, MK-801 also possessed stark sex-based differences in exposure which likely accounts for the increased sensitivity of female rats to MK-801 toxicity. This study confirms the safety of (2R,6R)-HNK over a broad dose range (up to 160 mg/kg) with no evidence of neurotoxicity. These findings indicate that ketamine-induced Olney’s lesion-type neurotoxicity may be dependent on the route of administration in acute and repeat-dose paradigms, as well as the relative pharmacokinetic exposure of ketamine. Future studies investigating NMDAR antagonist neurotoxicity should strongly consider taking sex and pharmacokinetics into account.

Declaration of Competing Interest

The authors declare competing financial interests. R.M. and C.A.Z. are listed as coinventors on a patent for the use of (2R,6R)-HNK, and other hydroxynorketamines in the treatment of depression. C.A.Z., R.M., T.G., C.T., P.Z., and P.M. are listed as coinventors on a patent application for the use of (2R,6R)-HNK and (2S,6S)-HNK in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorder. C.A.Z., R.M., T.G., C.T., P.Z., and P.M. are listed as coinventors on a patent application for the crystal forms and synthesis of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine. C.T. and P.M. are listed as coinventors on a patent application for the synthesis and purification of (2R,6R)-hydroxynorketamine.

Acknowledgements

This work was supported by the Division of Preclinical Innovation, National Center for Advancing Translational Sciences and the Center for Cancer Research, National Cancer Institute and the Intramural Research Programs of the National Institute of Mental Health and the National Institute of Aging. This article reflects the views of the author and should not be construed to represent FDA’s views or policies. The authors would like to thank Steve Van Adestine (Covance Laboratories, Inc.) for assisting with image capture.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ntt.2021.106993.

References


